Diabetic Retinopathy Treatment Market

Future Market Insights

Key Insight

The diabetic retinopathy treatment market is projected to grow from USD 5.6 billion in 2025 to USD 11.7 billion by 2035, at a CAGR of 7.6%. Non-Proliferative Diabetic Retinopathy (NPDR) – Moderate will dominate with a 42.8% market share, while anti-vascular endothelial growth factor (vegf) drug will lead the treatment type segment with a 39.8% share.

September 12, 2025

Anurag Sharma

250 Pages

Cite this Report

Diabetic Retinopathy Treatment Market

https://www.futuremarketinsights.com/reports/diabetic-retinopathy-treatment-market

License

Starting at US$ 5000

Buy Now

Summary ToC Companies

Key Players

Abbott Laboratories
Alimera Sciences Inc
Allergan plc
Bayer
Carl Zeiss Meditec AG
F. Hoffmann-La Roche Ag
Genentech Inc
The Vanguard Group
Novartis
Regeneron Pharmaceuticals

Methodology

Member of

Greater New York Chamber of Commerce

Recognized by

Awarded by

SILVER STEVIE® WINNER

Asia Pacific Stevie Awards - 2023

BRONZE STEVIE® Award

20th annual IBAs

Quick Contact

Chat on Whatsapp + 44 20 3769 9709 + 1 347 918 3531 Contact By Email

Get Free Sample PDF

Diabetic Retinopathy Treatment Market

Key Players

Similar Industry Reports